MarketBeat
18 Aug 2026, 05:03 UTC · 11w ago
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
Impact · against what's priced in
TransMedics' strategic pivot toward the kidney market and European expansion provides a significant long-term growth catalyst that extends the company's total addressable market. While near-term margin compression is expected due to increased kidney program spending, the clear roadmap to a 30% operating margin and the scale of the kidney opportunity likely outweigh short-term costs.
- TMDX+0.60
No priced-in read yet
- In context
The company identifies a $2 billion opportunity in the kidney market targeting 30,000 annual procedures and utilizes the PAD Aviation acquisition to bid on tens of millions of euros in European tenders.
Read from the article alone
